Hillmen P, Rawstron AC, Brock K, Muñoz-Vicente S, Yates FJ, Bishop R, et al. Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study. J Clin Oncol. 2019;37:2722–9.
Google Scholar
Eichhorst B, Niemann CU, Kater AP, Fürstenau M, von Tresckow J, Zhang C, et al. First-line venetoclax combinations in chronic lymphocytic leukemia. N Engl J Med. 2023;388:1739–54.
Google Scholar
Use of minimal residue disease as an endpoint in chronic lymphocytic leukaemia studies – Scientific guideline | European Medicines Agency (EMA). https://www.ema.europa.eu/en/use-minimal-residue-disease-endpoint-chronic-lymphocytic-leukaemia-studies-scientific-guideline (accessed 2025-02-19).
April 12, 2024 Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement – 04/12/2024 | FDA. https://www.fda.gov/advisory-committees/advisory-committee-calendar/april-12-2024-meeting-oncologic-drugs-advisory-committee-meeting-announcement-04122024 (accessed 2025-02-27).
Guidelines Detail. NCCN. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1478 (accessed 2025-08-17).
Drugs | FDA https://www.fda.gov/drugs (accessed 2025-08-17).
Shao Y, Kay NE, Gale RP, Liang Y. Challenges in analyzing clinical trials testing bruton tyrosine-kinase-inhibitors in chronic lymphocytic leukaemia. Leukemia. 2024;38:1469–73.
Google Scholar
Yang S, Kay NE, Shi M, Hanson CA, Gale RP. Is unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory approvals and therapy decisions in chronic lymphocytic leukaemia (CLL)? Leukemia. 2022;36:2743–7.
Google Scholar
Parikh SA, Gale RP, Kay NE. Chronic lymphocytic leukemia in 2020: a surfeit of riches? Leukemia. 2020;34:1979–83.
Google Scholar
Xie W, Halabi S, Tierney JF, Sydes MR, Collette L, Dignam JJ, et al. A systematic review and recommendation for reporting of surrogate endpoint evaluation using meta-analyses. JNCI Cancer Spectr. 2019;3:pkz002.
Google Scholar
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62:e1–34.
Google Scholar
Liu N, Zhou Y, Lee JJ. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2021;21:111.
Google Scholar
Short NJ, Zhou S, Fu C, Berry DA, Walter RB, Freeman SD, et al. Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis. JAMA Oncol. 2020;6:1890.
Google Scholar
Wei LJ. The accelerated failure time model: a useful alternative to the cox regression model in survival analysis. Stat Med. 1992;11:1871–9.
Google Scholar
Carroll R, Lawson AB, Jackson CL, Zhao S. Assessment of spatial variation in breast cancer-specific mortality using Louisiana SEER data. Soc Sci Med. 2017;193:1–7.
Google Scholar
Wang M, Li Z, Lu J, Zhang L, Li Y, Zhang L. Spatial-temporal Bayesian accelerated failure time models for survival endpoints with applications to prostate cancer registry data. BMC Med Res Methodol. 2024;24:86.
Google Scholar
Bürkner P-C. Brms: an R package for bayesian multilevel models using stan. J Stat Softw. 2017;80:1–28.
Google Scholar
Gelman A. Bayesian Data Analysis, Third edition.; Chapman & Hall/CRC texts in statistical science; CRC Press: Boca Raton, 2014.
Collett D Modelling Survival Data in Medical Research. 0 ed. Chapman and Hall/CRC; 2015.
Google Scholar
Wang J, Im Y, Wang R, Ma S. Partial Hepatectomy and Ablation for Survival of Early-Stage Hepatocellular Carcinoma Patients: A Bayesian Emulation Analysis. Life (Basel). 2024;14:661.
Google Scholar
Ibrahim JG, Chen M-H, Sinha D. Bayesian Survival Analysis; Springer Series in Statistics; Springer New York: New York, NY, 2001.
Shapiro SS, Wilk MB, Chen MHJ. A Comparative Study of Various Tests for Normality. Journal of the American Statistical Association. 1968.
A’Hernl RP, Ebbs SR, Baum’ MB. Does Chemotherapy Improve Survival in Advanced Breast Cancer? A Statistical Overview.
Fox J, Weisberg S. An R Companion to Applied Regression, Third edition.; SAGE: Los Angeles London New Delhi Singapore Washington, DC Melbourne, 2019.
Wickham H. Ggplot2; Use R!; Springer International Publishing: Cham, 2016.
Institute for Quality and Efficiency in Health Care (IQWiG. Validity of Surrogate Endpoints in Oncology. In Institute for Quality and Efficiency in Health Care: Executive Summaries [Internet]. 2011.
Belin L, Tan A, De Rycke Y, Dechartres A. Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review. Br J Cancer. 2020;122:1707–14.
Google Scholar
Seymour JF, Kipps TJ, Eichhorst BF, D’Rozario J, Owen CJ, Assouline S, et al. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. Blood. 2022;140:839–50.
Google Scholar
Fürstenau M, Kater AP, Robrecht S, von Tresckow J, Zhang C, Gregor M, et al. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2024;25:744–59.
Google Scholar
Al-Sawaf O, Robrecht S, Zhang C, Olivieri S, Chang Y, Fink A, et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study. Blood. 2024;144:1924–35.
Niemann CU, Munir T, Moreno C, Owen C, Follows GA, Benjamini O, et al. Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24:1423–33.
Google Scholar
Wang XV, Hanson CA, Tschumper RC, Lesnick CE, Braggio E, Paietta EM, et al. Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. Blood. 2021;138:2810–27.
Google Scholar
Desai S, Mo C, Gaglione EM, Yuan CM, Stetler-Stevenson M, Tian X, et al. Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 study. Leuk Lymphoma. 2021;62:1816–27.
Google Scholar
Stilgenbauer S, Tausch E, Roberts AW, Davids MS, Eichhorst B, Hallek M, et al. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for Del(17p) chronic lymphocytic leukemia. Blood Adv. 2024;8:1992–2004.
Google Scholar
Thompson PA, Srivastava J, Peterson C, Strati P, Jorgensen JL, Hether T, et al. Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. Blood. 2019;134:1951–9.
Google Scholar
Egle A, Steurer M, Melchardt T, Weiss L, Gassner FJ, Zaborsky N, et al. Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study. Ann Hematol. 2018;97:1825–39.
Google Scholar
Varghese AM, Howard DR, Pocock C, Rawstron AC, Follows G, McCarthy H, et al. Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation. Br J Haematol. 2017;176:573–82.
Google Scholar
Mauro FR, Molica S, Soddu S, Ilariucci F, Coscia M, Zaja F, et al. High rate of mrd-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2). Haematologica. 2020;105:2671–4.
Google Scholar
Fraser G, Cramer P, Demirkan F, Silva RS, Grosicki S, Pristupa A, et al. Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia. 2019;33:969–80.
Google Scholar
Munir T, Howard DR, McParland L, Pocock C, Rawstron AC, Hockaday A, et al. Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL. Leukemia. 2017;31:2085–93.
Google Scholar
Howard DR, Munir T, McParland L, Rawstron AC, Milligan D, Schuh A, et al. Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL. Leukemia. 2017;31:2416–25.
Google Scholar
Abrisqueta P, Villamor N, Terol MJ, González-Barca E, González M, Ferrà C, et al. Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. Blood. 2013;122:3951–9.
Google Scholar
Woyach JA, Perez Burbano G, Ruppert AS, Miller C, Heerema NA, Zhao W, et al. Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL. Blood. 2024;143:1616–27.
Google Scholar
Michallet A-S, Letestu R, Le Garff-Tavernier M, Campos L, Ticchioni M, Dilhuydy M-S, et al. A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial. Blood Adv. 2023;7:3936–45.
Google Scholar
Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, et al. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. Haematologica. 2022;107:2108–20.
Google Scholar
Thompson PA, Tam CS, O’Brien SM, Wierda WG, Stingo F, Plunkett W, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127:303–9.
Google Scholar
Munir T, Moreno C, Owen C, Follows G, Benjamini O, Janssens A, et al. Impact of minimal residual disease on progression-free survival outcomes after fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in the GLOW study. J Clin Oncol. 2023;41:3689–99.
Google Scholar
Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C, et al. Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the murano phase III study. J Clin Oncol. 2019;37:269–77.
Google Scholar
Kutsch N, Robrecht S, Fink A, Lange E, Weide R, Kiehl MG, et al. The role of trephine bone marrow biopsies in the era of measurable residual disease—results from the CLL10 Trial of the German CLL Study Group (GCLLSG). HemaSphere. 2024;8:e126.
Robak T, Blonski JZ, Gora-Tybor J, Jamroziak K, Dwilewicz-Trojaczek J, Tomaszewska A, et al. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood. 2006;108:473–9.
Google Scholar
Badoux XC, Keating MJ, Wang X, O’Brien SM, Ferrajoli A, Faderl S, et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood. 2011;117:3016–24.
Google Scholar
Parikh SA, Keating MJ, O’Brien S, Wang X, Ferrajoli A, Faderl S, et al. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood. 2011;118:2062–8.
Google Scholar
Cartron G, Letestu R, Dartigeas C, Tout M, Mahé B, Gagez A-L, et al. Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French innovative leukemia Organization (FILO) Study. Haematologica. 2018;103:e356–e359.
Google Scholar
Stilgenbauer S, Leblond V, Foà R, Böttcher S, Ilhan O, Knauf W, et al. Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study. Leukemia. 2018;32:1778–86.
Google Scholar
Langerak AW, Ritgen M, Goede V, Robrecht S, Bahlo J, Fischer K, et al. Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab. BLOOD. 2019;133:494–7.
Google Scholar
Jindal N, Lad DP, Malhotra P, Prakash G, Khadwal A, Jain A, et al. Randomized controlled trial of individualized, low dose, fixed duration lenalidomide maintenance versus observation after frontline chemo-immunotherapy in CLL. Leuk Lymphoma. 2021;62:1674–81.
Google Scholar
Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase Ii pivotal trial. J Clin Oncol. 2018;36:1973–80.
Google Scholar
Brown JR, Seymour JF, Jurczak W, Aw A, Wach M, Illes A, et al. Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia. N Engl J Med. 2025;392:748–62.
Böttcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012;30:980–8.
Google Scholar
Fischer K, Ritgen M, Al-Sawaf O, Robrecht S, Tandon M, Fink A-M, et al. Quantitative analysis of minimal residual disease (MRD) shows high rates of undetectable MRD after fixed-duration chemotherapy-free treatment and serves as surrogate marker for progression-free survival: a prospective analysis of the randomized CLL14 trial. Blood. 2019;134:36.
Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127:208–15.
Google Scholar
Eichhorst B, Fink A-M, Bahlo J, Busch R, Kovacs G, Maurer C, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17:928–42.
Google Scholar
Shanafelt TD, Wang XV, Hanson CA, Paietta EM, O’Brien S, Barrientos J, et al. Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood. 2022;140:112–20.
Google Scholar
Hillmen P, Pitchford A, Bloor A, Broom A, Young M, Kennedy B, et al. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24:535–52.
Google Scholar
Munir T, Girvan S, Cairns DA, Bloor A, Allsup D, Varghese AM, et al. Measurable residual disease-guided therapy for chronic lymphocytic leukemia. N Engl J Med. 2025;393:1177–90.
Google Scholar
Handunnetti SM, Lew TE, Lin VS, Anderson MA, Carney D, Wolf M, et al. An undetectable pb mrd status should be the therapeutic goal with venetoclax therapy in relapsed/ refractory CLL. Hematol Oncol. 2019;37:108–9.
Google Scholar
Strati P, Keating MJ, O’Brien S, Burger JA, Ferrajoli A, Jain N, et al. Bone marrow may be more informative than peripheral blood to evaluate minimal residual disease during 1st and 2nd year follow up after first-line fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia. Blood. 2013;122:1621.
Google Scholar
Abrisqueta P, Villamor N, Terol MJ, González-Barca E, González M, Ferrà C, et al. Prognostic impact of the MRD status after induction treatment with rituximab plus fludarabine, cyclophosphamide and mitoxantrone (R-FCM) in patients with chronic lymphocytic leukemia receiving rituximab maintenance therapy. Blood. 2012;120:3930.
Google Scholar
Sharman JP, Brander DM, Mato AR, Ghosh N, Schuster SJ, Kambhampati S, et al. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial. Lancet Haematol. 2021;8:e254–e266.
Google Scholar
Sharman JP, Egyed M, Jurczak W, Skarbnik A, Patel K, Flinn IW, et al. Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN. Blood. 2025;146:1276–85.
Google Scholar
Simon F, Ligtvoet R, Robrecht S, Cramer P, Kutsch N, Fürstenau M, et al. End point surrogacy in first-line chronic lymphocytic leukemia. J Clin Oncol. 2025;43:381–91.
Google Scholar
Dimier N, Delmar P, Ward C, Morariu-Zamfir R, Fingerle-Rowson G, Bahlo J, et al. A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL. Blood. 2018;131:955–62.
Google Scholar
Lu P, Wang S, Franzen CA, Venkataraman G, McClure R, Li L, et al. Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication. Blood Cancer J. 2021;11:39.
Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022;6:3440–50.
Google Scholar
O’Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016;17:1409–18.
Google Scholar
Ghia P, Pluta A, Wach M, Lysak D, Kozak T, Simkovic M, et al. ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38:2849–61.
Google Scholar
Chiorazzi N, Chen S-S, Rai KR. Chronic lymphocytic leukemia. Cold Spring Harb Perspect Med. 2021;11:a035220.
Google Scholar
